Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US5898032A · kind A · utility
38Cited by
6References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 23, 1997 |
| Grant date | Apr 27, 1999 |
| Priority date | — |
| Expiry date | Jun 23, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.